Literature DB >> 22770219

Acetylation-dependent regulation of Skp2 function.

Hiroyuki Inuzuka1, Daming Gao, Lydia W S Finley, Wen Yang, Lixin Wan, Hidefumi Fukushima, Y Rebecca Chin, Bo Zhai, Shavali Shaik, Alan W Lau, Zhiwei Wang, Steven P Gygi, Keiko Nakayama, Julie Teruya-Feldstein, Alex Toker, Marcia C Haigis, Pier Paolo Pandolfi, Wenyi Wei.   

Abstract

Aberrant Skp2 signaling has been implicated as a driving event in tumorigenesis. Although the underlying molecular mechanisms remain elusive, cytoplasmic Skp2 correlates with more aggressive forms of breast and prostate cancers. Here, we report that Skp2 is acetylated by p300 at K68 and K71, which is a process that can be antagonized by the SIRT3 deacetylase. Inactivation of SIRT3 leads to elevated Skp2 acetylation, which leads to increased Skp2 stability through impairment of the Cdh1-mediated proteolysis pathway. As a result, Skp2 oncogenic function is increased, whereby cells expressing an acetylation-mimetic mutant display enhanced cellular proliferation and tumorigenesis in vivo. Moreover, acetylation of Skp2 in the nuclear localization signal (NLS) promotes its cytoplasmic retention, and cytoplasmic Skp2 enhances cellular migration through ubiquitination and destruction of E-cadherin. Thus, our study identifies an acetylation-dependent regulatory mechanism governing Skp2 oncogenic function and provides insight into how cytoplasmic Skp2 controls cellular migration.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22770219      PMCID: PMC3595190          DOI: 10.1016/j.cell.2012.05.038

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  69 in total

Review 1.  Targeting the PI3K-Akt pathway in human cancer: rationale and promise.

Authors:  Ji Luo; Brendan D Manning; Lewis C Cantley
Journal:  Cancer Cell       Date:  2003-10       Impact factor: 31.743

2.  Characterization of the murine SIRT3 mitochondrial localization sequence and comparison of mitochondrial enrichment and deacetylase activity of long and short SIRT3 isoforms.

Authors:  Jianjun Bao; Zhongping Lu; Joshua J Joseph; Darin Carabenciov; Christopher C Dimond; Liyan Pang; Leigh Samsel; J Philip McCoy; Jaime Leclerc; Phuongmai Nguyen; David Gius; Michael N Sack
Journal:  J Cell Biochem       Date:  2010-05       Impact factor: 4.429

3.  Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence.

Authors:  Hui-Kuan Lin; Zhenbang Chen; Guocan Wang; Caterina Nardella; Szu-Wei Lee; Chia-Hsin Chan; Chan-Hsin Chan; Wei-Lei Yang; Jing Wang; Ainara Egia; Keiichi I Nakayama; Carlos Cordon-Cardo; Julie Teruya-Feldstein; Pier Paolo Pandolfi
Journal:  Nature       Date:  2010-03-18       Impact factor: 49.962

4.  Skp2 is oncogenic and overexpressed in human cancers.

Authors:  M Gstaiger; R Jordan; M Lim; C Catzavelos; J Mestan; J Slingerland; W Krek
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-17       Impact factor: 11.205

5.  Stat3 dimerization regulated by reversible acetylation of a single lysine residue.

Authors:  Zheng-Long Yuan; Ying-Jie Guan; Devasis Chatterjee; Y Eugene Chin
Journal:  Science       Date:  2005-01-14       Impact factor: 47.728

6.  Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation.

Authors:  Haojie Huang; Kevin M Regan; Fang Wang; Diping Wang; David I Smith; Jan M A van Deursen; Donald J Tindall
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-24       Impact factor: 11.205

7.  Correlation of Skp2 with carcinogenesis, invasion, metastasis, and prognosis in colorectal tumors.

Authors:  Jia-Qing Li; Fei Wu; Tsutomu Masaki; Akihito Kubo; Jiro Fujita; Dan A Dixon; R Daniel Beauchamp; Toshihiko Ishida; Shigeki Kuriyama; Katsumi Imaida
Journal:  Int J Oncol       Date:  2004-07       Impact factor: 5.650

8.  Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease.

Authors:  Anupriya Agarwal; Thomas G P Bumm; Amie S Corbin; Thomas O'Hare; Marc Loriaux; Jonathan VanDyke; Stephanie G Willis; Jutta Deininger; Keiichi I Nakayama; Brian J Druker; Michael W Deininger
Journal:  Blood       Date:  2008-06-17       Impact factor: 22.113

9.  Casein kinase 1 is a novel negative regulator of E-cadherin-based cell-cell contacts.

Authors:  Sophie Dupre-Crochet; Angélica Figueroa; Catherine Hogan; Emma C Ferber; Carl Uli Bialucha; Joanna Adams; Emily C N Richardson; Yasuyuki Fujita
Journal:  Mol Cell Biol       Date:  2007-03-12       Impact factor: 4.272

10.  The human silent information regulator (Sir)2 homologue hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase.

Authors:  Bjorn Schwer; Brian J North; Roy A Frye; Melanie Ott; Eric Verdin
Journal:  J Cell Biol       Date:  2002-08-19       Impact factor: 10.539

View more
  104 in total

1.  S-phase kinase-associated protein 2 promotes cell growth and motility in osteosarcoma cells.

Authors:  Lu Ding; Rong Li; Rongxin Sun; Yang Zhou; Yubo Zhou; Xiaoping Han; Yong Cui; Wu Wang; Qing Lv; Jingping Bai
Journal:  Cell Cycle       Date:  2017-08-03       Impact factor: 4.534

2.  Tumor suppressor SPOP ubiquitinates and degrades EglN2 to compromise growth of prostate cancer cells.

Authors:  Linli Zhang; Shan Peng; Xiangpeng Dai; Wenjian Gan; Xin Nie; Wenyi Wei; Guoqing Hu; Jianping Guo
Journal:  Cancer Lett       Date:  2017-01-13       Impact factor: 8.679

3.  Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function.

Authors:  Naoe T Nihira; Kohei Ogura; Kouhei Shimizu; Brian J North; Jinfang Zhang; Daming Gao; Hiroyuki Inuzuka; Wenyi Wei
Journal:  Sci Signal       Date:  2017-02-14       Impact factor: 8.192

4.  The SCFβ-TRCP E3 ubiquitin ligase complex targets Lipin1 for ubiquitination and degradation to promote hepatic lipogenesis.

Authors:  Kouhei Shimizu; Hidefumi Fukushima; Kohei Ogura; Evan C Lien; Naoe Taira Nihira; Jinfang Zhang; Brian J North; Ailan Guo; Katsuyuki Nagashima; Tadashi Nakagawa; Seira Hoshikawa; Asami Watahiki; Koji Okabe; Aya Yamada; Alex Toker; John M Asara; Satoshi Fukumoto; Keiichi I Nakayama; Keiko Nakayama; Hiroyuki Inuzuka; Wenyi Wei
Journal:  Sci Signal       Date:  2017-01-03       Impact factor: 8.192

5.  Acetylation Enhances TET2 Function in Protecting against Abnormal DNA Methylation during Oxidative Stress.

Authors:  Yang W Zhang; Zhihong Wang; Wenbing Xie; Yi Cai; Limin Xia; Hariharan Easwaran; Jianjun Luo; Ray-Whay Chiu Yen; Yana Li; Stephen B Baylin
Journal:  Mol Cell       Date:  2017-01-19       Impact factor: 17.970

6.  A novel thyroid hormone receptor isoform, TRβ2-46, promotes SKP2 expression and retinoblastoma cell proliferation.

Authors:  Zhengke Li; Dong-Lai Qi; Hardeep P Singh; Yue Zou; Binghui Shen; David Cobrinik
Journal:  J Biol Chem       Date:  2019-01-14       Impact factor: 5.157

7.  Phosphorylation of ezrin-radixin-moesin-binding phosphoprotein 50 (EBP50) by Akt promotes stability and mitogenic function of S-phase kinase-associated protein-2 (Skp2).

Authors:  Gyun Jee Song; Kristen L Leslie; Stacey Barrick; Tatyana Mamonova; Jeremy M Fitzpatrick; Kenneth W Drombosky; Noah Peyser; Bin Wang; Maria Pellegrini; Philip M Bauer; Peter A Friedman; Dale F Mierke; Alessandro Bisello
Journal:  J Biol Chem       Date:  2014-12-09       Impact factor: 5.157

Review 8.  Targeting the ubiquitin pathway for cancer treatment.

Authors:  Jia Liu; Shavali Shaik; Xiangpeng Dai; Qiong Wu; Xiuxia Zhou; Zhiwei Wang; Wenyi Wei
Journal:  Biochim Biophys Acta       Date:  2014-12-04

Review 9.  Mitochondrial Sirtuins in Cancer: Emerging Roles and Therapeutic Potential.

Authors:  Jasmine George; Nihal Ahmad
Journal:  Cancer Res       Date:  2016-04-20       Impact factor: 12.701

10.  Aneuploidy, oncogene amplification and epithelial to mesenchymal transition define spontaneous transformation of murine epithelial cells.

Authors:  Hesed M Padilla-Nash; Nicole E McNeil; Ming Yi; Quang-Tri Nguyen; Yue Hu; Danny Wangsa; David L Mack; Amanda B Hummon; Chanelle Case; Eric Cardin; Robert Stephens; Michael J Difilippantonio; Thomas Ried
Journal:  Carcinogenesis       Date:  2013-04-25       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.